EP3490534A1 - Composition orale d'anticorps anti-tnf alpha - Google Patents
Composition orale d'anticorps anti-tnf alphaInfo
- Publication number
- EP3490534A1 EP3490534A1 EP17749664.3A EP17749664A EP3490534A1 EP 3490534 A1 EP3490534 A1 EP 3490534A1 EP 17749664 A EP17749664 A EP 17749664A EP 3490534 A1 EP3490534 A1 EP 3490534A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- release
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Definitions
- the present invention relates to compositions for oral administration of an anti-tumor necrosis factor alpha (TNFa) antibody.
- TNFa anti-tumor necrosis factor alpha
- TNF alpha is a pro-inflammatory cytokine that is secreted by and interacts with cells of the immune system. TNFa has been shown to be involved in many human diseases, including chronic inflammatory diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and multiple sclerosis.
- Several anti-TNFa antibodies are currently under development. Two antibodies are already commercially available: infliximab (Remicade®), and adalimumab (Humira®), in injectable forms subcutaneously or intravenously.
- anti-TNFa antibody therapy particularly systemic, may have undesirable side effects, including the occurrence of bacterial infections such as tuberculosis (Jarequi-Amezaga et al., Journal of Crohn's and Colitis). 2013, 7 (3), 208-212), or Listeria infections (Abreu et al., Journal of Crohn's and colitis, 2013, 7 (2), 175-182) or Candida (Huang et al., Journal of Pediatric Gastroenterology and Nutrition, 2013, 56 (4), pages 23-6).
- anti-TNFa antibody formulations for oral administration are currently under development. However none is marketed and there is still a need to provide compositions to improve the efficacy and / or safety of anti-TNFa antibodies administered orally.
- the subject of the present invention is therefore a pharmaceutical composition for oral administration, comprising an anti-tumor necrosis factor alpha (TNFa) antibody and at least one or more pharmaceutically acceptable excipients chosen from the group comprising: a carboxymethyl-dextran, a chitosan, a cyclodextrin or a combination thereof.
- TNFa anti-tumor necrosis factor alpha
- the antibody dissociates from human TNFa with the following constants: Kd less than 1 x 10 "8 M (preferably less than 1 x 10" 9 M, more preferably less than 1 x 10 "10 M, still more preferably less than 1x10” 11 M ) and Koff of 1 x 10 "3 sec" 1 or less, both determined by a resonant test surface plasmon ( "surface plasmon resonance”).
- the antibody is neutralizing. In particular, it neutralizes the biological function of TNFa by blocking its interaction with TNF receptors p55 and p75 located on the cell surface.
- the antibody-neutralizing capacity can be tested by a standard test, in particular by measuring the ability of the antibody to neutralize human TNF cytotoxicity on human fibroblast cells (L929) with an IC50 of 1x10 "7 M or less, preferably less than 1 x 10 "8 M, more preferably less than 1 x 10" 9 M, or even more preferably less than 1 x 10 "10 M.
- the anti-TNF alpha antibody is a monoclonal antibody.
- the anti-TNF alpha antibody according to the invention may be an antibody of a mammal such as a mouse, or may be humanized, or entirely human. In a particularly advantageous embodiment, the anti-TNF alpha antibody is a human monoclonal antibody.
- the anti-TNF alpha antibody according to the invention has a heavy chain comprising SEQ ID No.1 and a light chain comprising SEQ ID No.2.
- SEQ ID NO: 1 SEQ ID No.1
- the anti-TNF alpha antibody may be adalimumab, infliximab or golimumab.
- the anti-TNF alpha antibody is adalimumab.
- Adalimumab is an immunoglobulin G (IgG) composed of two light kappa chains and two lgG1 heavy chains.
- the antibody used in the present invention can be produced by any technique well known to those skilled in the art.
- the antibody according to the invention is a recombinant antibody.
- the antibody may be produced recombinantly in a host cell, transformed with one or more vectors that allow the expression and / or the secretion of the nucleotide sequences coding for the heavy chain and / or the light chain of the antibody.
- the vector generally comprises a promoter, translation initiation and termination signals, as well as appropriate transcriptional regulatory regions. It is stably maintained in the host cell and may optionally have particular signals that specify the secretion of the translated protein. These different elements are chosen and optimized by those skilled in the art depending on the cellular host used.
- Such vectors are prepared by methods commonly used by those skilled in the art, and the resulting clones can be introduced into a suitable host by standard methods, such as lipofection, electroporation, the use of polycationic agents, thermal shock, or chemical methods.
- the cellular host may be chosen from prokaryotic or eukaryotic systems, for example bacterial cells, but also yeast cells or animal cells, in particular non-human mammalian cells.
- Mammalian cells preferred for the production of the monoclonal antibody are the YB2 / 0 rat line, the CHO hamster line, in particular the CHO dhfr- and CHO Lecl3 lines, PER.C6TM (Crucell), 293, K562, NSO, SP2 / 0, BHK or COS. Insect cells can also be used.
- the anti-TNF alpha antibody is produced in non-human mammalian mammary epithelial cells. Another mode of production is the expression of the recombinant antibody in transgenic organisms, for example in plants (Ayala et al., Methods Mol Biol., 2009; 483, pp.
- the anti-TNF alpha antibody is produced in the milk of a non-human transgenic mammal.
- the antibody is produced in the milk of non-human transgenic mammals genetically modified to produce this glycoprotein.
- the mammal may be for example a goat, ewe, females of bison, buffalo, camel, llama, mouse, rat, or a cow, sow, rabbit, or mare.
- the antibody is produced in transgenic goat's milk.
- the secretion of the antibody by the mammary glands involves controlling the expression of the antibody in a tissue-dependent manner.
- control methods are well known to those skilled in the art.
- the control of the expression is carried out thanks to sequences allowing the expression of the glycoprotein in a particular tissue of the animal. These include promoter sequences of "WAP”, “ ⁇ -casein”, “ ⁇ -lactoglobulin” and optionally signal peptide type sequences.
- the antibody is produced in the mammary glands of a transgenic goat, using an expression vector comprising the sequence of the two chains, under the control of a 5 ' ⁇ -casein promoter.
- a method for extracting proteins of interest from transgenic animal milk is described in patent EP 0 264 166.
- more than 4 grams of antibody per liter of milk are produced, advantageously more than 5, 10, 15, 20, 25, 30, 35 grams per liter, even more advantageously up to 70 grams per liter.
- the antibody produced by animal transgenesis in particular in the mammary glands of a transgenic goat, is in the form of a population of anti-TNF ⁇ antibodies which exhibit glycosylation with a high level of galactosylation, by example greater than 60%, preferably greater than 70%, more preferably at least 80%.
- the fucosylation rate of all the antibodies in the population is at least 50%, and in particular at least 60%.
- the anti-TNFa antibody population comprises antibodies which comprise mono-galactosyl N-glycans.
- the anti-TNFa antibody population comprises antibodies which comprise bi-galactosylated N-glycans.
- the ratio of the level of galactosylation of the antibodies of the population and the fucosylation rate of the antibodies of the population is between 1, 0 to 1, 4.
- at least 35% of the antibodies in the population comprise bi-galactosyl N-glycans and at least 25% of the antibodies in the population comprise mono-galactosyl N-glycans.
- the sialylation rate of the antibodies is at least 50%, preferably at least 70%, or at least 90%.
- the antibodies are totally sialylated.
- N-glycans are not regulated by coding, as is the case with proteins, but is primarily dependent on the expression and activity of specific glycosyltransferases in a cell.
- a glycoprotein such as the Fc fragment of an antibody, normally exists as a heterogeneous population of glycoforms that carry different glycans on the same protein backbone.
- a highly galactosylated antibody population is an antibody population in which the galactosylation level of all antibodies in the population is at least 50%, at least 60%, at least 70% at least 80%, at least 90%, up to 100% galactosylation.
- the galactosylation rate of all the antibodies in the population is at least 60%.
- the level of galactosylation can be determined with the following formula:
- N represents the number of N-glycans analyzed on a chromatogram, for example a normal phase high performance liquid chromatography spectrum (NP HPLC),
- “Galactose number” represents the number of galactoses on the glycan antenna corresponding to the peak
- “Number of A” represents the number of N-acetylglucosamine units on the antenna of the glycan form corresponding to the peak (excluding the two N-acetylglucosamine units of the common framework structure of glycans)
- % Relative area is the percentage of the area under the corresponding peak.
- the level of galactosylation of the antibodies of the antibody population can be determined, for example, by releasing the N-glycans from the antibodies, by solving the N-glycans on a chromatogram, by identifying the N-glycanic oligosaccharide motif which corresponds to a specific peak, determining the intensity of the peak and applying the data to the formula mentioned above.
- Antibodies that are galactosyl include antibodies that have mono- galactosyl N-glycans and bi-galactosyl N-glycans.
- the highly galactosylated antibody population comprises antibodies that include mono-galactosylated N-glycans, which may or may not be sialylated.
- the highly galactosylated antibody population at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, up to 100% of the N-glycans of the antibodies include mono-galactosylated N-glycans.
- at least 25% of the antibodies comprise mono-galactosyl N-glycans.
- the population includes antibodies that include bi-galactosylated N-glycans, which may or may not be sialylated.
- at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, up to 100% of the N-glycans of the antibodies include bi-galactosylated N-glycans.
- the population of highly galactosylated antibodies at least 35% of the antibodies comprise bi-galactosylated N-glycans.
- the population comprises antibodies which comprise mono-galactosylated N-glycans, which may or may not be sialylated, and antibodies which include bi-galactosylated N-glycans, which may or may not be sialylated.
- At least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, up to 99% of the N-glycans of the antibodies comprise mono-galactosylated N-glycans, and at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least less than 70%, at least 80%, at least 90%, up to 99% of the N-glycans of the antibodies comprise bi-galactosylated N-glycans.
- At least 25% of the antibodies comprise mono-galactosyl N-glycans, and at least 35% of the antibodies comprise bi-galactosyl N-glycans.
- the anti-TNF ⁇ antibody is produced by the mammary epithelial cells of a non-human transgenic mammal and is produced exogenously in the mammary gland.
- the therapeutic antibodies thus produced have a high level of galactosylation, and possibly increased levels of alpha-2,6 sialic acid terminal linkages on their Fc-linked glycans residues.
- the antibody has a high mannose glycosylation profile.
- a "high mannose glycosylation profile” refers to an antibody that contains at least one oligomannose or antibody composition in which at least 30% of the antibody contains at least one oligomannose. In some embodiments at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the antibodies' sugars are non-fucosylated oligomannoses. In other embodiments less than 50%, 40%, 30%, 20%, 10%, 5% or less of the sugars of the antibodies contain fucose. In another embodiment, the antibodies have a low fucose content and a high oligomannose content.
- At least 30%, 40%, 50%, 60%, 70%, 80% or 90% or more of the antibodies' sugars are oligomannose and less than 50%, 40%, 30%, 20%, 10% or 5% of the sugars of the antibodies contain fucose.
- at least 30%, 40%, 50%, 60%, 70%, 80% or 90% or more of the antibodies' sugars are of nonfucosylated oligomannose and less than 50%, 40%, 30%, 20%, 10% or 5% of the sugars of the antibodies contain fucose.
- the oligosaccharides containing mannose may advantageously contain from 5 to 9 mannoses.
- An oligosaccharide containing Y mannoses is described by the term ManY.
- oligosaccharides containing mannose may include Man5, Man6, Man7, Man8 and Man9.
- the antibody such as Adalimumab produced transgenically, has a high content of Man6.
- the major sugar is Man5.
- at least 10%, 15%, or more of the sugars are Man5.
- at least 20% of the sugars are of Man5.
- the major sugar is Man6.
- At least 10%, 15%, or more of the sugars of the transgenically produced antibody are Man6.
- at least 20% of the sugars are of Man6.
- the major sugar is Man7.
- at least 10%, 15% or more of the sugars are Man7.
- at least 20% of the sugars are Man7.
- High affinity means an affinity at least equal to 2 ⁇ 10 6 M -1 , preferably at least 2 ⁇ 10 7 M -1 , 2 ⁇ 10 8 M -1 or 2 ⁇ 10 9 M -1 , as determined by Scatchard analysis. or BIAcore technology (Label-free surface plasmon resonance based technology). This receptor is found on many immune cells, including natural killer cells, macrophages, neutrophils, and mast cells.
- anti-TNF ⁇ antibody populations produced in mammary gland epithelial cells are superior, in terms of binding to soluble TNF ⁇ , to antibodies produced in cells that are not mammary gland epithelial cells.
- anti-TNF ⁇ antibody populations produced in mammary gland cells are superior, in terms of transmembrane TNF ⁇ binding, to antibodies produced in cells that are not mammary gland epithelial cells.
- the anti-TNF ⁇ antibody may be the antibody described in the international application WO2014 / 125374.
- the pharmaceutical composition of the invention as defined above is devoid of at least one of the following excipients: caprylic acid or a salt of caprylate, glucose, fructose, galactose, mannose, sorbose, sucrose, ribose, deoxyribose, sucrose, maltitol, inulin, lecithin, trehalose, lactose, maltose, raffinose, mannitol, sorbitol, glycerol, arabitol, lactitol, xylitol, polypropylene glycol, polyethylene glycol, polyoxyethylene sorbitan fatty acid ester, polysorbate 20, polysorbate 80, poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene alkylphenylpolyoxyethylene ethers, polyoxyethylene-polyoxypropylene copolymer, sodium dodecylsulphate, sodium succinate, sodium chloride
- lacking means that the composition of the invention does not contain caprylic acid or salt of caprylate, glucose, fructose, galactose, mannose, sorbose, sucrose , ribose, deoxyribose, sucrose, maltitol, inulin, lecithin, trehalose, lactose, maltose, raffinose, mannitol, sorbitol, glycerol, arabitol, lactitol, xylitol , polypropylene glycol, polyethylene glycol, polyoxyethylene sorbitan fatty acid ester, polysorbate 20, polysorbate 80, poloxamers, polyoxyethylene alkyl ethers, alkylphenylpolyoxyethylene ethers, copolymer of polyoxyethylene-polyoxypropylene, sodium dodecylsulphate, sodium succinate, sodium chloride, sodium citrate, citric acid
- the pharmaceutical composition of the invention as defined above is devoid of anticoagulant-effect molecule, in particular EDTA.
- the pharmaceutical composition of the invention as defined above is devoid of surfactant, in particular polysorbate 20, polysorbate 80 or poloxamer.
- the pharmaceutical composition of the invention as defined above is devoid of a laxative molecule, in particular mannitol, sorbitol, glycerol, lactitol or xylitol.
- excipients mentioned above have in particular been discarded because of their anticoagulant activity such as EDTA, or because they present a risk of developing Crohn's disease when ingested, such as in particular polysorbate 20, the polysorbate 80 or poloxamer, or because these excipients may have a laxative effect, such as in particular mannitol, maltitol, lactitol, xylitol or sorbitol.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha), as active principle, and
- TNF-alpha monoclonal antibody anti-tumor necrosis factor alpha
- CMD carboxymethyl dextran
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha), as active ingredient, and
- chitosan as a pharmaceutically acceptable excipient.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha), as active ingredient, and
- cyclodextrin as a pharmaceutically acceptable excipient.
- the cyclodextrin may be chosen from ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, one of their derivatives, such as in particular a hydroxypropyl, hydroxyethyl, ethyl or methyl derivative, a cyclodextrin. sulfobutyl beta-ether, a branched cyclodextrin, a cyclodextrin-based polymer or a mixture thereof.
- the cyclodextrin may be hydroxypropyl- ⁇ -cyclodextrin (or HPBCD).
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle, and
- HPBCD Hydroxypropyl-3-cyclodextrin
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle, and
- CMD carboxymethyl dextran
- HPBCD ⁇ hydroxypropyl-3-cyclodextrin
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle, and
- CMD carboxymethyl-dextran
- chitosan a combination of carboxymethyl-dextran (CMD) and chitosan, as a pharmaceutically acceptable excipient.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle, and
- a combination of a cyclodextrin, especially ⁇ hydroxypropyl- ⁇ -cyclodextrin (HPBCD) and chitosan, as a pharmaceutically acceptable excipient especially ⁇ hydroxypropyl- ⁇ -cyclodextrin (HPBCD) and chitosan, as a pharmaceutically acceptable excipient.
- HPBCD ⁇ hydroxypropyl- ⁇ -cyclodextrin
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody to tumor necrosis factor alpha (TNF-alpha) as the active ingredient, and
- CMD carboxymethyl dextran
- HPBCD ⁇ hydroxypropyl-3-cyclodextrin
- chitosan a combination of carboxymethyl dextran (CMD), cyclodextrin, especially ⁇ hydroxypropyl-3-cyclodextrin (HPBCD) and chitosan, as a pharmaceutically acceptable excipient.
- the pharmaceutical composition for oral administration may further comprise at least one amino acid.
- the amino acid may be chosen from arginine, glycine, lysine, histidine, glutamate, glutamine, asparagine, isoleucine, leucine, alanine, phenylalanine, threonine, tyrosine, tryptophan, methionine, serine, proline, cysteine, selenocysteine, proline, valine, a derivative salt thereof, such as a hydrochloride or a phosphate, or a mixture of these.
- the amino acid is chosen from hydrophilic amino acids.
- the amino acid is glycine or one of these derived salts, such as glycine hydrochloride.
- the amino acid is arginine or one of these derived salts, such as arginine hydrochloride.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- TNF-alpha monoclonal antibody anti-tumor necrosis factor alpha
- CMD carboxymethyl dextran
- an amino acid in particular glycine, optionally in its hydrochloride form.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- TNF-alpha monoclonal antibody anti-tumor necrosis factor alpha
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- cyclodextrin in particular hydroxypropyl-3-cyclodextrin (HPBCD), as a pharmaceutically acceptable excipient
- an amino acid in particular glycine, optionally in its hydrochloride form.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- TNF-alpha monoclonal antibody anti-tumor necrosis factor alpha
- CMD carboxymethyl dextran
- HPBCD hydroxypropyl-3-cyclodextrin
- an amino acid in particular glycine, optionally in its hydrochloride form.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- TNF-alpha monoclonal antibody anti-tumor necrosis factor alpha
- CMD carboxymethyl-dextran
- chitosan a combination of carboxymethyl-dextran (CMD) and chitosan, as a pharmaceutically acceptable excipient
- an amino acid in particular glycine, optionally in its hydrochloride form.
- the pharmaceutical composition for oral administration comprises: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- TNF-alpha monoclonal antibody anti-tumor necrosis factor alpha
- HPBCD hydroxypropyl- ⁇ -cyclodextrin
- chitosan as a pharmaceutically acceptable excipient
- an amino acid in particular glycine
- the pharmaceutical composition for oral administration consists of: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle, and
- CMD carboxymethyl dextran
- the pharmaceutical composition for oral administration consists of: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- CMD carboxymethyl dextran
- a cyclodextrin in particular hydroxypropyl-3-cyclodextrin (HPBCD).
- HPBCD hydroxypropyl-3-cyclodextrin
- the pharmaceutical composition for oral administration consists of: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle,
- CMD carboxymethyl dextran
- HPBCD hydroxypropyl-3-cyclodextrin
- an amino acid in particular glycine, optionally in its hydrochloride form.
- the pharmaceutical composition for oral administration consists of: a monoclonal antibody anti-tumor necrosis factor alpha (TNF-alpha) as active principle, and
- chitosan as a pharmaceutically acceptable excipient.
- the pharmaceutical composition according to the invention is in solid form.
- the pharmaceutical composition in solid form can be obtained by any technique well known to those skilled in the art.
- the pharmaceutical composition in solid form can be obtained by lyophilization, drying atomization or by spray drying.
- compositions of the present invention may be in any of the galenical forms normally used for oral administration, especially in the form of tablets, capsules, capsules, lozenges, powder, syrup or any form for solid oral preparation or in any form of oral preparation.
- the composition is in the form of a prolonged-release and / or delayed-release formulation.
- extended-release and / or delayed-release formulation means a dosage form adapted to targeted release in the gastrointestinal tract, and in particular the intestine.
- intestine is meant here all parts of the intestine, especially the colon.
- Such compositions are particularly useful in the treatment of inflammatory bowel diseases because they allow local action at the site of the infection (especially small intestine or colon). They also limit the passage of antibodies in the bloodstream, limiting the side effects related to anti-TNFa antibodies.
- the pharmaceutical composition in the form of a sustained-release and / or delayed-release formulation comprising the anti-TNF ⁇ antibody and at least one pharmaceutically acceptable excipient as described above may be formulated into solid dosage forms, such as tablets or capsules.
- the pharmaceutical composition in the form of a prolonged-release and / or delayed-release formulation comprising the anti-TNF ⁇ antibody and at least one pharmaceutically acceptable excipient as described above may further comprise at least one coating agent. .
- the coating agent by virtue of its resistance to the acidic pH of the stomach (between 1 and 3), makes it possible in particular to protect the composition comprising the anti-TNF ⁇ antibody and at least one pharmaceutically acceptable excipient of the acidic pH of the stomach and their release in the small intestine and the colon where the pH values are close to 7.
- the coating agent may be an agent film-forming agent, preferably gastro-soluble or a coating agent.
- the coating agent may be chosen from the group comprising: acrylic acid derivatives, methacrylic acid derivatives, ethyl acrylate derivatives, hydroxypropyl methylcellulose derivatives, polyvinyl acetate derivatives phatlates; poly (methyl acrylate -co-methyl methacrylate -co-methacrylic acid, poly (methacrylate acid -co-methyl methacrylate), sold especially under the names Eudragit ® S100 ® Eudragit FS30D, Eudragit ® L100, Eudragit ® L12,5 Eudragit ® L30D- 55, Eudragit ®, L100-55, Eudragit ® S12,5, hydroxypropylmethylcellulose (HPMCP), succinyl hydroxypropylmethylcellulose acetate, also known as HPMCAS and marketed under the name AQOAT ®, Shellac or a mixture thereof .
- HPMCAS hydroxypropylmethylcellulose
- the pharmaceutical composition in the form of a sustained-release and / or delayed-release formulation comprising the anti-TNF ⁇ antibody and at least one pharmaceutically acceptable excipient as described above may comprise a monolayer of a single coating agent, a monolayer consisting of a mixture of several coating agents, a multilayer consisting of a single coating agent; a multilayer consisting of a mixture of several different coating agents or a superposition of several monolayers consisting of a single coating agent.
- formulations can be used which are coated with degradable polymers by the colon microorganisms (more particularly by bacterial enzymes such as azoreductases and glycosidases), for example azo polymers having a high degree of hydrophilicity.
- Gels and hydrogels may also be used, including polysaccharide hydrogels.
- compositions of the invention may comprise or be combined with other therapeutic agents useful in the treatment of inflammatory diseases or autoimmune diseases.
- Another aspect of the invention relates to a method of preparing a sustained release and / or delayed release pharmaceutical composition, said method comprising: a) a step of mixing the anti-TNF alpha antibody with one or more pharmaceutically acceptable excipients selected from the group consisting of: carboxymethyl dextran, chitosan, cyclodextrin or a combination thereof. b) a drying step, particularly by atomization, of the composition obtained in step a), c) A coating step.
- step c) of coating can be carried out by any technique well known to those skilled in the art.
- the coating step c) can be carried out by coating, by coating, in particular by adding film-forming agents, by spraying, by enteric coating in a fluidized bed, by dry coating, by stripping coating.
- dry coating is meant any solvent-free process using a mechanical action to coat a solid pharmaceutical form with a discrete or continuous layer of inert or active powders. For example, it makes it possible to obtain composite particles comprising several layers of different compositions.
- step c) of coating can be carried out with one or more coating agents by applying: a monolayer consisting of a single coating agent, or
- a multilayer consisting of a mixture of several coating agents, or a superposition of several monolayers consisting of a single coating agent, each of the monolayers having a different coating agent.
- a sustained release and / or delayed release pharmaceutical composition comprising an anti-tumor necrosis factor alpha (TNFa) antibody and at least one or more pharmaceutically acceptable excipients selected from the group consisting of: a carboxymethyl-dextran , a chitosan, a cyclodextrin or a combination thereof, for its use in the treatment of inflammatory diseases or autoimmune diseases.
- TNFa anti-tumor necrosis factor alpha
- Another aspect of the invention is a method of treating inflammatory diseases or autoimmune diseases comprising administering to a patient in need thereof a sustained release pharmaceutical composition comprising an anti-tumor necrosis factor alpha antibody. (TNFa) and at least one or more pharmaceutically acceptable excipients selected from the group consisting of: carboxymethyl dextran, chitosan, cyclodextrin or a combination thereof.
- Figure 1 Results of the functional test at T0, T + 2 hours and T + 5 hours after passing through the SHI ME® system.
- the formulations are presented in the following order (from left to right): 1 / without excipients, 21 HPBCD, 3 / CMD, 4 / HPBCD + CMD, 5 / HPCD + EDTA, 6 / Polysorbate 20 + EDTA + Trehalose, 7 / Poloxamer 188 + EDTA + Trehalose, 8 / CMD + Polysorbate 20 + Arginine, 9 / CMD + Polysorbate 20 + Glycine, 10 / Chitosan.
- anti-TNF ⁇ antibodies used are those described in the international application WO2014 / 125374 of the Applicant.
- HPBCD Hydroxypropyl-beta-cyclodextrin
- Poloxamer 188 1 .25 mg / mL
- the anti-TNF ⁇ antibody formulations in the presence of the different excipients are set at 5, 40 and 50 ° C for 3, 7 and 14 days.
- the formulations are the subject of the following analyzes:
- SEC Size Exclusion Chromatography
- anti-TNF ⁇ antibody formulation samples are diluted to 2 mg / mL in PBS buffer (10mM Na 2 HPO 4 + 1.8mM KH 2 PO 4 + 2.7mM KCl + 137mM NaCl) and then centrifuged for 5 minutes at 15,000g. The supernatants are transferred into flasks, deposited in chromatography gel for separation and then each peak is detected by absorbance measurement at 280 nm.
- DLS Dynamic Light Scattering
- the functional activity test consists of an antibody binding test to membrane TNF ⁇ proteins with flow cytometric detection, making it possible to determine the conservation of the binding activity of the antibody to its target.
- Poloxamer 188 1, 25 mg / mL Good Good
- results considered to be good make it possible to preserve both the quantity and the quality of the protein, especially after stress at 50 ° C. for 14 days (preservation of the quantity of proteins and preservation of the distribution profile of the forms of the protein).
- the total protein level decreased significantly for formulations comprising carbopol, lecithin, SLS, albumin, inulin, and maltitol, indicating the formation of insoluble proteins that were removed by centrifugation.
- Pic 1 Pic 2 Pic 3 Pic 2 Pic 3 monomers (others) (others) Monomers (others) (others)
- SLS sulfate
- results in DLS confirm that formulations comprising Carbopol (971P and 974P), inulin, lecithin, maltitol, do not maintain the stability of the anti-TNFa antibody.
- the other formulations show good preservation of the protein, particularly in the presence of excipients CMD, chitosan, glycine or HPBCD.
- Formulations considered compatible (good results only) in SEC and DLS are then tested for functional activity.
- the formulations comprising the excipients Carbopol 971P, Carbopol 974P, lecithin, inulin and maltitol are determined to be incompatible with the anti-TNF ⁇ antibody, because of the formation of white flakes (flocculation of the formulation), indicating that the protein of interest and / or the protein and its excipient have precipitated.
- the test makes it possible to evaluate the formation of dry powder and the possible need for addition of protectants (surfactants and / or amino acids) during the drying step.
- protectants surfactants and / or amino acids
- the drying atomization of the placebo solutions was optimized on a laboratory-scale drying sprayer type B-290 (Buchi, Flawil, Switzerland).
- the test is then carried out with the excipients and with the addition of anti-TNFa antibodies.
- the dried spray drying particles are collected in a tank attached to a cyclone. After the process, the powder is cooled to room temperature and transferred to a glass bottle.
- the powders obtained have a residual moisture content of less than 15% by weight.
- the powders are then reconstituted in acetate buffer (500 ⁇ for 5 mg of powder) to control the possible negative impact of the spray drying step. All the powders have a good preservation of the quantity and the quality of the anti-TNFa antibody protein.
- Example 2 The formulations of Example 2, previously selected to provide the stability of the anti-TNF ⁇ antibody and dried, are then tested for oral administration. In particular, an assay was performed in a model mimicking the ascending colon (SHIME® System from ProDigest) to study the effect of each formulation.
- SHIME® System from ProDigest
- Jurkat cells transfected to express the membrane TFNa are incubated with 100 ⁇ l of anti-TNF antibody at different concentrations (0 to 100 ⁇ l / ml, final concentration) at 4 ° C. for 30 minutes. After washing the goat anti-Fc IgG antibody coupled with phycoerythrin (100 ⁇ l of a 1: 100 dilution) was added at 4 ° C for 30 minutes.
- the cells are washed and the mean fluorescence intensity (MFI) measured by flow cytometry.
- MFI mean fluorescence intensity
- a response curve is established with the reference antibody (anti-TNF ⁇ antibody in PBS buffer) to define the minimum concentration of antibodies giving the plateau. All samples are tested at 0.125 ⁇ g ml. The results are expressed as a percentage with respect to a reference and standardized.
- formulations comprising surfactants (polysorbate 20 or Poloxamer 188) because these, although perfectly tolerated in intravenous or subcutaneous administration, are suspected to be responsible, when ingested, for an increased risk of developing inflammatory bowel disease such as Crohn's disease.
- formulations comprising molecules with anticoagulant effect, such as EDTA formulations comprising polyols, in particular mannitol, maltitol, sorbitol, glycerol, lactitol, or xylitol which may have a laxative effect.
- Example 5 Oral formulation with release in the gastrointestinal tract The following formulations:
- the coating agents tested are preferably enteric coatings because of the acid sensitivity of the antibody, in particular derivatives of acrylic acids, derived from methacrylic acids, ethyl acrylate derivatives, hydroxypropyl methylcellulose derivatives, derivatives thereof.
- polyvinyl acetate phatlates in particular Eudragit® FS30D, Eudragit® S100, Eudragit® L100, Eudragit®L12.5, Eudragit® L30D-55, Eudragit® L100-55, Eudragit® S12.5, HPMC AS (AQOAT®), HPMCP®, Shellac.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1657442A FR3054444A1 (fr) | 2016-07-29 | 2016-07-29 | Composition orale d'anticorps anti-tnf alpha |
PCT/EP2017/068918 WO2018019900A1 (fr) | 2016-07-29 | 2017-07-26 | Composition orale d'anticorps anti-tnf alpha |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3490534A1 true EP3490534A1 (fr) | 2019-06-05 |
Family
ID=57348856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17749664.3A Withdrawn EP3490534A1 (fr) | 2016-07-29 | 2017-07-26 | Composition orale d'anticorps anti-tnf alpha |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190270801A1 (fr) |
EP (1) | EP3490534A1 (fr) |
CA (1) | CA3031033A1 (fr) |
FR (1) | FR3054444A1 (fr) |
WO (1) | WO2018019900A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220192992A1 (en) * | 2019-04-01 | 2022-06-23 | Vta Labs, Llc | Protection of monoclonal antibody integrity against evaporative solidification, compression and proteolysis by dextran and cyclodextrin derivatives |
WO2020243393A1 (fr) * | 2019-05-30 | 2020-12-03 | Vta Labs, Llc | Conception d'un système d'administration par voie orale unique contenant un anticorps monoclonal pour le traitement simultané de la maladie de crohn et de la colite ulcéreuse |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264166B1 (fr) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Animaux transformés génétiquement sécrétant une protéine désirée dans le lait |
US8192718B1 (en) * | 2005-01-04 | 2012-06-05 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
AU2007250536A1 (en) * | 2006-05-16 | 2007-11-22 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
EP2807190B1 (fr) * | 2012-01-23 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisées contenant des anticorps anti-ang2 |
MX363700B (es) * | 2012-03-07 | 2019-03-29 | Cadila Healthcare Ltd | Formulaciones farmaceuticas de anticuerpos tnf-alfa. |
EP2956480B1 (fr) | 2013-02-13 | 2019-09-04 | Laboratoire Français du Fractionnement et des Biotechnologies | Anticorps anti-tnf alpha hautement galactosylés et leurs utilisations |
-
2016
- 2016-07-29 FR FR1657442A patent/FR3054444A1/fr active Pending
-
2017
- 2017-07-26 US US16/320,297 patent/US20190270801A1/en not_active Abandoned
- 2017-07-26 CA CA3031033A patent/CA3031033A1/fr not_active Abandoned
- 2017-07-26 WO PCT/EP2017/068918 patent/WO2018019900A1/fr active Search and Examination
- 2017-07-26 EP EP17749664.3A patent/EP3490534A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
FR3054444A1 (fr) | 2018-02-02 |
US20190270801A1 (en) | 2019-09-05 |
WO2018019900A1 (fr) | 2018-02-01 |
CA3031033A1 (fr) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3157954B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
Kulkarni et al. | Advances in the colon-targeted chitosan based multiunit drug delivery systems for the treatment of inflammatory bowel disease | |
EP1492511B3 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) | |
EP1194125B1 (fr) | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif | |
WO2010073119A1 (fr) | Composition pharmaceutique stable comprenant au moins un anticorps monoclonal et au moins un polysaccharide amphiphile comprenant des substituants hydrophobes | |
US20170165269A1 (en) | Sustained release drug delivery system | |
EP1524968A2 (fr) | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) | |
WO2018121578A1 (fr) | Préparation pharmaceutique comprenant de maniere stable un anticorps monoclonal cd147 | |
JP2016510001A (ja) | シスプラチン充填キトサンナノ粒子を含む標的化された頬側送達 | |
FR2759293A1 (fr) | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie | |
EP3490534A1 (fr) | Composition orale d'anticorps anti-tnf alpha | |
JP2019514963A (ja) | 免疫抑制化合物および組成物としてのグリコーゲンおよびフィトグリコーゲンナノ粒子ならびにそれらの使用方法 | |
JP2006526009A (ja) | 改良された経口及び経粘膜デリバリーのためのクラドリビン製剤 | |
CA2800757C (fr) | Composition d'immunoglobulines humaines stabilisee | |
WO2018121580A1 (fr) | Préparation pharmaceutique comprenant un anticorps monoclonal cd147 | |
FR2934161A1 (fr) | Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules. | |
WO2021168996A1 (fr) | Nanocapsules de catalase et méthodes d'utilisation | |
WO2023061462A1 (fr) | Formulation pharmaceutique stable comprenant un anticorps monoclonal anti-cd147 | |
WO2018115476A1 (fr) | Antagoniste spécifique de tlr4 dans le traitement du myélome multiple | |
FR2952936A1 (fr) | Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol | |
WO2019121966A1 (fr) | Composition pharmaceutique pour administration orale d'anticorps pour le traitement des maladies du tractus gastro-intestinal | |
WO2018178594A1 (fr) | Prévention d'une infection par le virus respiratoire syncytial dans les voies respiratoires supérieures | |
US20220089706A1 (en) | Anti-elastin antibodies and methods of use | |
EA044207B1 (ru) | Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора суспензии | |
FR2715067A1 (fr) | Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190131 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: JAUME, CECILE Inventor name: HANDKE, NADEGE Inventor name: GAUCHER, CHRISTINE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200116 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |